GlassScriptPhysician profile
Leo B Bustad
NPI 1144245903
$817.72
in general payments reported to CMS, 2019-2025
22 companies · $30.51 in 2025
The $30.51 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $117 · 2021: $183 · 2022: $159 · 2023: $126 · 2024: $28.22 · 2025: $30.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $184.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $208.56 | 2019-2025 | Breztri, Brilinta, Airsupra |
| Amgen INC. | $79.69 | 2020-2024 | Evenity, Prolia, Repatha |
| E.R. Squibb & Sons, L.L.C. | $64.75 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $52.47 | 2019-2023 | |
| Pfizer INC. | $42.44 | 2021-2023 | |
| Novo Nordisk INC | $39.12 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.45 | 2019-2020 | |
| Cook Medical LLC | $32.88 | 2022-2025 | Rosen |
| Lilly USA, LLC | $29.04 | 2022-2023 | Jardiance |
| Bard Peripheral Vascular, INC. | $27.15 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $23.35 | 2021 | |
| Nestle Healthcare Nutrition INC. | $23.32 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $22.00 | 2019 | |
| Amarin Pharma, INC. | $20.81 | 2021 | |
| Abbott Laboratories | $18.75 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $16.53 | 2023 | Embold Fibered |
| Philips North America LLC | $16.21 | 2022 | |
| Medtronic, INC. | $15.91 | 2021 | |
| Alkermes, INC. | $14.29 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.52 | 2019 | |
| Genentech USA, INC. | $11.38 | 2021 | |
| Merck Sharp & Dohme LLC | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leo Bustad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.